(Reuters) – Valeant Pharmaceuticals International Inc said on Thursday it has raised its bid for worldwide rights to a prostate cancer vaccine owned by bankrupt drugmaker Dendreon Corp.
Drugmaker Valeant raises bid for Dendreon cancer vaccine
(Reuters) – Valeant Pharmaceuticals International Inc said on Thursday it has raised its bid for worldwide rights to a prostate cancer vaccine owned by bankrupt drugmaker Dendreon Corp.
No comments:
Post a Comment